Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12-Week, Single-Blind, Placebo-Controlled, Randomized Study to Evaluate the Safety, Tolerability, and Physiological Regulation of an Amino Acid Food Product, AXA1665, in Subjects With Mild and Moderate Hepatic Insufficiency

Next Previous
Trial Profile

A 12-Week, Single-Blind, Placebo-Controlled, Randomized Study to Evaluate the Safety, Tolerability, and Physiological Regulation of an Amino Acid Food Product, AXA1665, in Subjects With Mild and Moderate Hepatic Insufficiency

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AXA 1665 (Primary)
  • Indications Hepatic encephalopathy
  • Focus Adverse reactions
  • Sponsors Axcella Health

Most Recent Events

  • 24 May 2021 Results published in the Axcella Health Media Release.
  • 24 May 2021 According to an Axcella Health media release, data from the study were presented at the Digestive Disease Week (DDW) 2021 Annual Meeting by Dr. Arun Sanyal.
  • 23 May 2021 Results assessing safety, tolerability and physiological impact of AXA1665 in Child-Pugh A and B subjects presented at the Digestive Disease Week 2021

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top